United Health Products Receives CE Mark Approval for HemoStyp® Product Now Approved for Use in European Economic Area

Henderson, Nevada – March 13,2018 – United Health Products, Inc. (OTCQB: UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has obtained Class III and CE mark approval for HemoStyp in the European Economic Area (EEA). The EEA comprises the 28 European Union members and a number of other countries.  Accordingly, HemoStyp is approved for use in internal surgical procedures in more than 30 countries.

“We are pleased to have received CE mark approval for HemoStyp, as this allows us to consider partnership and marketing proposals for the European market,” said Douglas K. Beplate, CEO, UHP.

The approval was received following the provision of all required documentation by the relevant regulatory agencies. The CE marking– CE is an acronym for the French term "Conformité Européenne"– certifies that a product has met EEA health, safety, and environmental requirements, which ensure consumer safety. Manufacturers in the EEA and abroad must meet CE marking requirements where applicable to market their products in Europe. A manufacturer who has gone through the conformity assessment process may affix the CE mark to its product. With the CE marking, the product may be marketed throughout the EEA, which comprises 33 countries with a population of exceeding 517 million and a GDP exceeding $17 trillion. For a list of countries that require the CE marking, see: CE Marking Countries.

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products Announces Completion of FDA PMA for HemoStyp®

Henderson, Nevada – February 5, 2018  United Health Products, Inc. (OTCQB: UEEC) ) today announced that, following its January 17 face-to- face meeting with FDA experts and officials, it has completed and submitted all materials relevant for the premarket approval (PMA) for HemoStyp. The PMA program is designed to confirm the safety of the HemoStyp product for use in internal human procedures. UHP has submitted additional inspection and registration forms to the CtQ Pilot program for final approval and confirmation. The PMA submission is for the approval of Class III indication and internal surgical use of Hemostyp.

The CtQ program is a sub-program of the PMA umbrella specific to facility and production safety. The estimated sales for internal surgical markets for hemostatic products (global hemostatic agents market) in 2017 are expected to be more than $7 billion. HemoStyp belongs to a subset of these markets whose 2017 sales are estimated at approximately $2.8 Billion, and are expected to nearly double to approximately $5.5 Billion by 2022. Overall, the global hemostatic agents market is estimated to grow at 7.1% annually, to reach $8.3 billion by 2022. http://industryarc.com/Report/15189/hemostats-market.html).

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products Issues FDA Update

Henderson, Nevada – January 22, 2018 – United Health Products, Inc. (OTCQB: UEEC) manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that, following a face-to-face meeting between FDA and key UHP representatives, it will pursue its PMA class III filing under the FDA's CtQ Pilot program for use in internal surgical procedures. Further, the company has decided to withdraw from its class II extension of use application with the FDA. It was determined that the PMA application allows a much broader range of indication than the prior 510K class II of expanded usage.proval for use in the Australian market within 30 days. 

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products Applying for Class III Designation for HemoStyp® by Australian TGA

Henderson, Nevada – December 12, 2017 – United Health Products, Inc. (OTCQB: UEEC) United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced it is applying to have HemoStyp designated as a Class III medical device with Australia’s Therapeutics Goods Administration (TGA, counterpart to the U.S. FDA).  Similar to the US FDA Class III application, this will allow for internal surgical use. The company’s Australian TGA consultants believe that UHP has the requisite test data and documentation to obtain rapid approval in Australia, and that HemoStyp® could obtain approval for use in the Australian market within 30 days. 

About TGA 
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. We carry out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard with the aim of ensuring that the Australian community has access, within a reasonable time, to therapeutic advances. https://www.tga.gov.au/about-tga

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com



FDA Selects HemoStyp® for CtQ Pilot Program

Henderson, Nevada – December 04, 2017 – United Health Products, Inc. (OTCQB: UEEC) manufacturer and marketer of HemoStyp®,  a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the  FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).

The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the post market inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a post market inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.

The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner.  This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html

Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application  – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review 

About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program 
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.

More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.

This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.

The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA's analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors. In simple terms, the review identified that an investment in quality has long-term payoffs.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com



United Health Products Announces Hemostyp® as a featured product of Dick’s Sporting Goods Advanced Wound Care Kit.

Henderson, Nevada – November 09, 2017 – United Health Products, Inc. (OTCQB: UEEC) announced that their 2’ x 4” Trauma Gauze™ product has been selected as the feature component for a new Advanced Wound Care Kit for Dick’s Sporting Goods (NYSE DKS). With today’s environment when the unexpected can happen anywhere, both in the wild and in urban areas, having an advanced trauma kit can be the difference between survival and tragedy. The Hemostyp® pouches will be included under the Field and Stream label. They will be available in their stores nationwide beginning in Feb 2018 and will be displayed in various locations throughout the stores.

About Dick’s Sporting Goods

Dick's Sporting Goods, Inc., sometimes shortened toDick's, is a Fortune 500 Americansporting goodsretailingcorporation headquartered inCoraopolis, PennsylvaniainGreater Pittsburgh. Dick's has 610 stores in 47 states (no stores inAlaska,Hawaii, andMontanaas of mid-March 2016) primarily in theEastern United States. The company also owns Golf Galaxy, Inc., a golf specialty retailer, with 82 stores in 30 states. The company also operates specialty chains True Runner andField & Stream. Founded in 1948 by Richard "Dick" Stack, the chain has expanded to become one of the largest sporting goods retailers in the world. www.dickssportinggoods.com.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com

 

United Health Products Issues FDA Submission Update

Henderson, Nevada – October 10, 2017 – United Health Products, Inc. (OTCQB: UEEC) a manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its current Expanded Indication Submission Class II application for HemoStyp for internal usage with the U.S. FDA continues to progress, and is in an advanced stage of review.  In addition, the company is pleased to announce that it has applied to the FDA’s new and innovative CtQ Pilot Program premarket approval PMA (Class III internal usage) for HemoStyp.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies—to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner.  This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 for internal surgical hemostatic products is estimated to be more than seven billion, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022.
(http://industryarc.com/Report/15189/hemostats-market.html)  

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com

 

United Health Products and Patterson/Animal Health International Launch Nationwide Marketing Campaign for HemoStyp® Products to U.S. Veterinary Healthcare Market

Henderson, Nevada – August 28, 2017 – United Health Products, Inc. (OTCQB: UEEC) a manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that, in conjunction with Patterson Veterinary/Animal Health International, Inc. (AHI), a subsidiary of Patterson Companies, Inc., it will conduct a marketing campaign to more than 8,000 companion animal clinics in the United States. 

Patterson Veterinary/AHI, United Health Products’ exclusive distributor to the U.S. animal health market, with a sales force more than 400 strong, will officially launch the campaign on September 1, which will last until year end 2017.  The campaign’s objective is to significantly increase sales of four HemoStyp products to the $10 Billion domestic veterinary healthcare market, and to attain  major market share gains in that market, one of the five that United Health Products serves.

 "We expect the marketing campaign with Patterson Veterinary/AHI to lead to significant sales in the third and fourth quarter of this year,” said Douglas K. Beplate, CEO. “Patterson Veterinary/AHI is one of the largest animal health companies in the United States, and we have been working diligently with them to make this program a success. Additional incentives to customers, coupled with our already leading cost effective pricing, should enable us to expand our footprint in this rapidly growing market. “ 

About Patterson Veterinary/Animal Health International
Patterson Veterinary/Animal Health International, Inc. is the premier animal health company in North America and has been serving the needs of customers for more than 40 years. No other distributor has a broader product offering. Patterson Veterinary/Animal Health International represents over 1,000 manufacturers that supply products focused on companion animal, equine, beef and dairy cattle, poultry, and swine. Patterson Veterinary/Animal Health International offers products ranging from vaccines and pharmaceuticals to state of the art equipment and software. Patterson Companies acquired Animal Health International in May of 2016 to become one of the largest Veterinary suppliers in the country.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
212-344-6464 ● PAN Consultants Ltd. 
p.niemetz@panconsultants.com 



United Health Products Inc. To File Late 2016 Audited Year End

Henderson, NV -  April 18, 2017 - United Health Products, Inc. (OTCQB: UEEC) announced that revenues for the fourth quarter of 2016 were approximately $252,000 and that the company is expecting to see increasing quarterly revenues for 2017. The company’s independent registered public accountants, Pritchett Siler & Hardy, P.C., are in the process of auditing 2016 financial statements and will present to the prior auditors RRBB for their opinion and approval. A late filing of our Form 10-K for the fiscal year ended December 31, 2016 is anticipated within the next two weeks. Douglas Beplate, CEO of UHP, commented that this is a major step forward for the company to have an auditing firm recognized in the auditing of public posted companies performing the audits as we move forward in creating market awareness and value.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444



United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  March 31, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday, April 4, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss present business, marketing plans for 2017, and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, April 5, by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  March 31, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday, April 4, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss present business, marketing plans for 2017, and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, April 5, by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  January 12, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial-in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday January 17, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss year end 2016, present business and current rollout to the veterinary market, marketing plans for 2017 and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, January 18 by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


UNITED HEALTH PRODUCTS INC TO HOST DIAL IN CORPORATE UPDATE

Henderson, NV -  October 11, 2016 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial in conference for shareholders, potential shareholders and those seeking to learn more about the company on October 13, 2016. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss the company’s current events and expansion of manufacturing capacities to meet the increase in current orders in the dental, veterinary, medical and retail markets. Management will also report on the future plans and efforts of the company to uplist to a higher exchange. The call in conference will be Thursday October 13th at 12:30 pm Eastern. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Friday October 14th by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444



United Health Products Inc. Announces Optimal Government Services Has Completed Their Distribution Agreement and Placed Stocking Orders

Henderson, NV -  May 16, 2016 - United Health Products, Inc. (OTCQB: UEEC) announced that Optimal Government Resources has signed their distribution agreement and placed an opening stocking order. In conjunction with this agreement, UHP HemoStyp® products are now listed under the DAPA contract #SP0200-09-H-0037. This begins an exciting new chapter for United Health Products and allows all US military, US government agencies and VA systems to order directly or via their Prime Vendor agreements.

About Optimal Government Services

Optimal GS is a participant in the Department of Defense (DOD) and Department of Veterans Affairs Medical/Surgical Prime Vendor Programs (MSPV), and the DOD and VA Pharmaceutical Prime Vendor Program (PPV). Optimal has commercial agreements with the National and Regional Prime Vendors to ensure highly efficient national distribution of its products to its Federal Customer Base. This customer base includes the DOD, all branches of the military, all federal government offices and programs. Optimal GS specializes in distribution of medical products through this network, utilizing the MSPV bridge contracts. The VA has created a major benefit to our Nation's Veterans by continuing to provide efficient and unparalleled medical supply support to VA medical centers nationwide. The program is mandatory for all VA medical centers. The MSPV program includes McKesson and Cardinal distribution.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

United Health Products Inc. Announces Optimal Government Services Has Completed Their Distribution Agreement and Placed Stocking Orders

Henderson, NV -  May 16, 2016 - United Health Products, Inc. (OTCQB: UEEC) announced that Optimal Government Resources has signed their distribution agreement and placed an opening stocking order. In conjunction with this agreement, UHP HemoStyp® products are now listed under the DAPA contract #SP0200-09-H-0037. This begins an exciting new chapter for United Health Products and allows all US military, US government agencies and VA systems to order directly or via their Prime Vendor agreements.

About Optimal Government Services

Optimal GS is a participant in the Department of Defense (DOD) and Department of Veterans Affairs Medical/Surgical Prime Vendor Programs (MSPV), and the DOD and VA Pharmaceutical Prime Vendor Program (PPV). Optimal has commercial agreements with the National and Regional Prime Vendors to ensure highly efficient national distribution of its products to its Federal Customer Base. This customer base includes the DOD, all branches of the military, all federal government offices and programs. Optimal GS specializes in distribution of medical products through this network, utilizing the MSPV bridge contracts. The VA has created a major benefit to our Nation's Veterans by continuing to provide efficient and unparalleled medical supply support to VA medical centers nationwide. The program is mandatory for all VA medical centers. The MSPV program includes McKesson and Cardinal distribution.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

United Health Products Announces Henry Schein Halas as Exclusive Distributor

Henderson, NV -  May 2, 2016 - United Health Products, Inc. (OTCQB: UEEC)) announced that they have signed Henry Schein Halas to an exclusive distribution agreement for all of United Health’s HemoStyp® products in conjunction with an initial stocking order for Australia and the African Continent. Henry Schein Halas was formed in 2006, when two of Australia's most innovative and successful dental businesses joined together. Built on decades of service to the profession by Halas Dental Ltd and Henry Schein Regional Ltd, the company maintains strong Australian management together with the commitment and investment of Henry Schein, the world's leading dental distributor. Their commitment to meeting and exceeding the service expectations of our customers is deeply ingrained in to their organization.  Henry Schein currently supplies over 80% of all dental practices in Australia and New Zealand and has 18 distribution centers in the region. Henry Schein is also the number one supplier in Australia and New Zealand in the Veterinary market. Henry Schein currently supplies more than 70% of the market.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444



United Health Products Announces Henry Schein Halas as Exclusive Distributor

Henderson, NV -  May 2, 2016 - United Health Products, Inc. (OTCQB: UEEC)) announced that they have signed Henry Schein Halas to an exclusive distribution agreement for all of United Health’s HemoStyp® products in conjunction with an initial stocking order for Australia and the African Continent. Henry Schein Halas was formed in 2006, when two of Australia's most innovative and successful dental businesses joined together. Built on decades of service to the profession by Halas Dental Ltd and Henry Schein Regional Ltd, the company maintains strong Australian management together with the commitment and investment of Henry Schein, the world's leading dental distributor. Their commitment to meeting and exceeding the service expectations of our customers is deeply ingrained in to their organization.  Henry Schein currently supplies over 80% of all dental practices in Australia and New Zealand and has 18 distribution centers in the region. Henry Schein is also the number one supplier in Australia and New Zealand in the Veterinary market. Henry Schein currently supplies more than 70% of the market.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444



United Health Products Inc. Announces Exclusive Distributor for India

Henderson, NV -  March 9, 2016 - United Health Products, Inc. (OTCQB: UEEC)) announced that it has entered into an exclusive distribution contract with CJ Global Capital LLC for India. The exclusive contract has a licensing fee and minimum yearly purchase requirements to maintain the rights to exclusivity to India for all of United Health Products Inc. HemoStyp® products. India's current health care industry is estimated to be USD 120 Billion and reach USD 230 Billion by 2020, with USD 5.5 Billion in Wound Care. Indian Government Expenditure on health care is the highest amongst all the developing countries. The expenses of this industry comprise 5.25% of the GDP. India is the second most populous country in the world, with over 1.277 billion people (2015), more than a sixth of the world's population. 

About CJ Global Capital LLC

CJ Global Capital LLC is a private international investment group headquartered in the United States specializing in projects involving patented products, new technologies, and large scale commercial real estate development. CJGC sales and marketing efforts for wholesaling will be led by David Champion, Marketing Director of Asia Pacific for Apollo RT Co., Ltd. Apollo RT Co. is a new Japanese owned company with manufacturing in China. David Champion is responsible for marketing and strategy for the Asian Market. In addition, David is Country Director for Apollo RT Co. business in Korea and Canada. David lived in India in the late 1990's and was employed by a company which is now part of GE Healthcare. He worked 13 years for Tyco Healthcare (later known as Covidien) in urological products (including incontinence products) and wound care products. CJGC various projects total USD 1 billion.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Announces Optimal Government Services as Exclusive Government Distributor

Henderson, NV -  January 21, 2016 - United Health Products, Inc. (OTCQB: UEEC)) announced that it has entered into a contract with Optimal Government Resources as the exclusive government distributor for its HemoStyp® product line.  Douglas Beplate, CEO of United Health Products Inc. added, “We are very pleased to be working with Optimal GS and to provide our HemoStyp® products to the U.S. Military and other U.S. Government agencies”.  The contract outlines the addition of HemoStyp® products to Optimal’s ERP, Service Order Module, included in the existing DAPA MS contract, registered in the Military and DOD Prime Vendor catalogs and assigned number registry with the Prime Vendor.

About Optimal Government Services

Optimal GS is a participant in the Department of Defense and Department of Veterans Affairs Medical/Surgical Prime Vendor Programs (MSPV), and the DOD and VA Pharmaceutical Prime Vendor Program (PPV). Optimal has commercial agreements with the National and Regional Prime Vendors to ensure highly efficient national distribution of its products to its Federal Customer Base. Optimal GS specializes in moving medical product through this network.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Inc. HemoStyp® Now Available From Patterson Veterinary

Henderson, NV -  November 19, 2015 - United Health Products, Inc. (OTCQB: UEEC)) announced that one of the nation's largest veterinary distribution companies Patterson Veterinary, a leading supplier of health supplies and equipment to veterinarians, has placed their initial stocking order with AMD Ritmed www.amdritmed.com, United Health's Sales and Marketing partner. Patterson Veterinary will be distributing and promoting the HemoStyp® products nationwide. Patterson Veterinary distributes consumable veterinary supplies, equipment, software, diagnostic products, vaccines and pharmaceuticals to veterinary clinics throughout the U.S. and U.K. Douglas Beplate CEO of United Health Products Inc. added, "We are very pleased to be working with Patterson Veterinary to provide HemoStyp® to clinics and Veterinarians across the country. Hemostyp® is the perfect product for providing faster bleeding control in small and large animals".

About Patterson Animal Health

Patterson is a Fortune 1000 member recognized by Forbes as one of America's Most Trusted Companies. Patterson's business presence includes the animal health and dental markets. The Company employs approximately 7,000 team members in North America and the U.K.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444